7/11/2013

Chiesi Farmaceutici secured exclusive rights to market uniQure's Glybera, the first gene therapy approved in Europe, for treatment of lipoprotein lipase deficiency. Chiesi and uniQure also agreed to jointly develop a hemophilia B gene therapy. UniQure will get 20% to 30% of net royalties on sales of both drugs.

Related Summaries